Huaxing Growth Capital
VC Fund
Beijing, China
Huaxing Growth Capital is a VC fund in Beijing focused on Health Care and EdTech. Huaxing Growth Capital is the flagship fund of China Renaissance's Investment Management segment and the principal private equity investment arm of China Renaissance. The fund manages fourUSD-denominated funds and four RMB-denominated funds. As of December 31, 2021, the company's private equity funds had an asset undermanagement("AUM") of over RMB 49 billion(~US$7.7 billion).
- Total investments:
- 28
- Last investment:
- Lead investor:
- 43%
- Fund size:
- $800M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Huaxing Growth Capital invests in
Stages Huaxing Growth Capital invests in
Countries Huaxing Growth Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ke Wei
|
|||
Jian Sun
|
|||
Lisa (Lingyun) Yuan
|
|||
|
Ming Lei
|
Investment Focus
Industry
- Health Care 5 (18%)
- EdTech 3 (11%)
- Software 3 (11%)
- Education 3 (11%)
- E-Commerce 3 (11%)
Stage
- Series B 9 (32%)
- Series C 9 (32%)
- Series D 7 (25%)
- Series A 2 (7%)
- Seed 1 (4%)
Country
- China 23 (82%)
- Australia 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ke Wei
Partner
|
Partner | Total investments: 1 | Find email | |
Fan Bao
Founder & Chief Executive Officer
|
Founder & Chief Executive Officer | Total investments: 2 | Find email | |
|
Jian Sun
Principal
|
Principal | Total investments: 0 | Find email | |
|
Lisa (Lingyun) Yuan
Partner and Investment Committee member of Huaxing Growth Capital at China Renaissance
|
Partner and Investment Committee member of Huaxing Growth Capital at China Renaissance | Total investments: 0 | Find email | |
|
Ming Lei
Principal
|
Principal | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pandomat
|
Pandomate is a cutting-edge company that combines trend product development and retail, culture and art brokerage, and new media communication and entertainment platforms. It offers a broad range of trend services. | $1.1M / Seed / Mar 19, 2024 | |
Insgeek
|
Insgeek is a one-stop service platform for corporate employee welfare insurance and health management. It is committed to providing intelligent employee benefits insurance and health management solutions through technological innovation. It integrates the products of various insurance companies, covering accidents, female births, and criticalillnesses, and provide a variety of cost-effective protection combinations.Founded in 2014, the company is headquartered in Beijing, China and currently has branches in Shanghai, Guangzhou, Wuhan, Xi'an, and other places, covering the whole country. | Series D / Sep 22, 2022 | |
Dian Xiaomi
|
Dian Xiaomi provides one-stop services for global e-commerce sellers. | $110M / Series D / Aug 16, 2022 | |
H.Extract
|
The company is dedicated to the R&D, promotion and sales of pharmaceutical ERP. Currently, as a leading brand of domestic pharmaceutical distribution with the Cloud ERP System, Romens has coverd more than 40 thousand pharmacies in China. The company established the strategic partnership with Tencent Cloud & Wechat Pay in May, 2016. Throughthe joint efforts, they will fasten the development of medicine distribution industry, especially pharmaceutical wholesale, chain-drugstores and the moblization of unit pharmacy. For the past 14 years, with the advanced technical strength, abundant experience in the management of chain-drugstores and profound insight into the industry, Romens has constantly expanded their target customers, including Harbin Pharmaceutical Group, Hainan Zhangzhongjing Dispensary, Sichuan Derentang and etc. | Series D / Jul 20, 2022 | |
|
Dian Xiaomi
|
Dian Xiaomi provides one-stop services for global e-commerce sellers. | $100M / Series C / Mar 01, 2022 | |
SceneRay
|
Sceneray Co. Ltd, located at Singapore Industrial Park in Suzhou China, is a medical device company dedicated to the design, development, and distribution of neuromodulation devices. The core team of Sceneray is made up by experts with deep China and overseas experiences in neuromodulation device development, manufacturing, and marketing. Scenerayholds many patents and keeps on exploring the frontiers in neuromodulation. Being an international high-tech medical and competitive company, Sceneray is dedicated to providing patients with high-quality and efficacious treatments. | $47.3M / Series D / Feb 16, 2022 | |
Chemsemi
|
ChemSemi develops 5G chips and semiconductor technologies. | $157.8M / Series A / Jan 21, 2022 | |
Dreame Technology
|
Dreame Technology produces premium hairdryers and vacuums in the style of Dyson. | $563.1M / Series C / Oct 21, 2021 | |
Creative Biosciences
|
Kang Liming Bio is a biomedical technology company that specializes in the development, production and sales of tumor screening diagnostic products such as colorectal cancer fecal non-invasive screening kits. | $87M / Series D / Oct 14, 2021 | |
Bluepha
|
Bluepha integrates bioengineering and data science to design, develop, and commercialize bio-based products that deliver value to a board range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics and more. | $77.1M / Series B / Aug 09, 2021 | |
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Huaxing Growth Capital invest in?
Huaxing Growth Capital invests primarily in Health Care, EdTech and Software startups, most often at Series B and Series C stage. Most of the 28 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Huaxing Growth Capital?
Public channels for Huaxing Growth Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Huaxing Growth Capital?
The team at Huaxing Growth Capital includes Ke Wei (Partner), Fan Bao (Founder & Chief Executive Officer) and Jian Sun (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
